Mdm‐2: “big brother” of p53

[1]  G. Zambetti,et al.  Analysis of the proportion of p53 bound to mdm-2 in cells with defined growth characteristics. , 1996, Oncogene.

[2]  A. Levine,et al.  mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein , 1996, Molecular and cellular biology.

[3]  M. Oren,et al.  Cell type‐specific inhibition of p53‐mediated apoptosis by mdm2. , 1996, The EMBO journal.

[4]  U. Moll,et al.  Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage , 1996, Molecular and cellular biology.

[5]  David E. Housman,et al.  Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours , 1996, Nature.

[6]  B. Wasylyk,et al.  MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest. , 1995, Oncogene.

[7]  Lawrence A. Donehower,et al.  Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53 , 1995, Nature.

[8]  Guillermina Lozano,et al.  Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53 , 1995, Nature.

[9]  M. Sasaki,et al.  MDM2 gene amplification in bone and soft‐tissue tumors: Association with tumor progression in differentiated adipose‐tissue tumors , 1995, International journal of cancer.

[10]  W. Foulkes,et al.  MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status. , 1995, British Journal of Cancer.

[11]  M. Imamura,et al.  p53 mutation, murine double minute 2 amplification, and human papillomavirus infection are frequently involved but not associated with each other in esophageal squamous cell carcinoma. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  Tony Kouzarides,et al.  Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein , 1995, Nature.

[13]  W. Sellers,et al.  Interaction between the retinoblastoma protein and the oncoprotein MDM2 , 1995, Nature.

[14]  A. Marchetti,et al.  mdm2 gene amplification and overexpression in non-small cell lung carcinomas with accumulation of the p53 protein in the absence of p53 gene mutations. , 1995, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[15]  R. Maestro,et al.  MDM2 overexpression does not account for stabilization of wild-type p53 protein in non-Hodgkin's lymphomas. , 1995, Blood.

[16]  A. Levine,et al.  Human TAFII31 protein is a transcriptional coactivator of the p53 protein. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[17]  G. Barnett,et al.  MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis. , 1995, Oncogene.

[18]  U. Moll,et al.  Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[19]  D. Carney,et al.  Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. , 1995, British Journal of Cancer.

[20]  S. Deb,et al.  N-terminal 130 amino acids of MDM2 are sufficient to inhibit p53-mediated transcriptional activation. , 1995, Oncogene.

[21]  M. Schwab,et al.  Non-syntenic amplification of MDM2 and MYCN in human neuroblastoma. , 1995, Oncogene.

[22]  A. Levine,et al.  The p53 and mdm‐2 genes in human testicular germ‐cell tumors , 1995, Molecular carcinogenesis.

[23]  W. Gerald,et al.  MDM2 and CDK4 gene amplification in Ewing's sarcoma , 1995, The Journal of pathology.

[24]  R. Tjian,et al.  p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. , 1995, Science.

[25]  A. Levine,et al.  Two domains of p53 interact with the TATA-binding protein, and the adenovirus 13S E1A protein disrupts the association, relieving p53-mediated transcriptional repression , 1995, Molecular and cellular biology.

[26]  A. Marchetti,et al.  mdm2 gene alterations and mdm2 protein expression in breast carcinomas , 1995, The Journal of pathology.

[27]  P. O'Connor,et al.  Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. , 1994, Science.

[28]  W. Cavenee,et al.  p53 gene mutation and mdm2 gene amplification are uncommon in medulloblastoma. , 1994, Cancer research.

[29]  T. Kinoshita,et al.  The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. , 1994, Blood.

[30]  B. Quesnel,et al.  Over‐expression of the MDM2 gene is found in some cases of haematological malignancies , 1994, British journal of haematology.

[31]  V. P. Collins,et al.  Analysis of glioma cell lines for amplification and overexpression of MDM2 , 1994, Genes, chromosomes & cancer.

[32]  C. Harris,et al.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.

[33]  O. Myklebost,et al.  MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. , 1994, Journal of the National Cancer Institute.

[34]  R. Takahashi,et al.  Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification. , 1994, Journal of the National Cancer Institute.

[35]  C. Cordon-Cardo,et al.  Altered patterns of MDM2 and TP53 expression in human bladder cancer. , 1994, Journal of the National Cancer Institute.

[36]  D. Lane,et al.  Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides. , 1994, Oncogene.

[37]  J. Landers,et al.  Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. , 1994, Oncogene.

[38]  F. Collin,et al.  Complex composition and co‐amplification of SAS and MDM2 in ring and giant rod marker chromosomes in well‐differentiated liposarcoma , 1994, Genes, chromosomes & cancer.

[39]  A. Levine,et al.  Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. , 1994, Genes & development.

[40]  M. Cole,et al.  The mdm-2 oncogene is translocated and overexpressed in a murine plasmacytoma cell line expressing wild-type p53. , 1994, Oncogene.

[41]  Mef Nilbert,et al.  MDM2 gene amplification correlates with ring chromosomes in soft tissue tumors , 1994 .

[42]  K. Kohn,et al.  The gadd and MyD genes define a novel set of mammalian genes encoding acidic proteins that synergistically suppress cell growth , 1994, Molecular and cellular biology.

[43]  Yi-Song Wang,et al.  WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. , 1994, Cancer research.

[44]  S. Park,et al.  DNA damage increases the levels of MDM2 messenger RNA in wtp53 human cells. , 1994, Cancer research.

[45]  M. Dyer,et al.  Lack of MDM2 amplification in human leukaemia , 1994, British journal of haematology.

[46]  J. Landers,et al.  Physical and functional interaction between wild-type p53 and mdm2 proteins , 1994, Molecular and cellular biology.

[47]  A. Levine,et al.  Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. , 1994, Cancer research.

[48]  R. Weinberg,et al.  Tumor spectrum analysis in p53-mutant mice , 1994, Current Biology.

[49]  P. Waber,et al.  Infrequency of MDM2 gene amplification in pediatric solid tumors and lack of association with p53 mutations in adult squamous cell carcinomas. , 1993, Cancer research.

[50]  A. Levine,et al.  The mdm-2 gene is induced in response to UV light in a p53-dependent manner. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[51]  S. Elledge,et al.  The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases , 1993, Cell.

[52]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[53]  A. Look,et al.  Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. , 1993, Cancer research.

[54]  S. Stass,et al.  The human MDM-2 oncogene is overexpressed in leukemias. , 1993, Blood.

[55]  N. Muñoz,et al.  p53 gene mutations and MDM2 amplification are uncommon in primary carcinomas of the uterine cervix. , 1993, The American journal of pathology.

[56]  D. Housman,et al.  p53-dependent apoptosis modulates the cytotoxicity of anticancer agents , 1993, Cell.

[57]  A. Levine,et al.  Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. , 1993, Oncogene.

[58]  W. Deppert,et al.  Upregulation of mdm-2 expression in Meth A tumor cells tolerating wild-type p53. , 1993, Oncogene.

[59]  A. Levine,et al.  Mapping of the p53 and mdm-2 interaction domains. , 1993, Molecular and cellular biology.

[60]  A. Levine,et al.  A comparison of the biological activities of wild‐type and mutant p53 , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[61]  M. Oren,et al.  Sequence‐specific DNA binding by p53: identification of target sites and lack of binding to p53 ‐ MDM2 complexes. , 1993, The EMBO journal.

[62]  A. Levine,et al.  The p53-mdm-2 autoregulatory feedback loop. , 1993, Genes & development.

[63]  G. Reifenberger,et al.  Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. , 1993, Cancer research.

[64]  C. Miller,et al.  The p53 activation domain binds the TATA box-binding polypeptide in Holo-TFIID, and a neighboring p53 domain inhibits transcription , 1993, Molecular and cellular biology.

[65]  C. Purdie,et al.  Thymocyte apoptosis induced by p53-dependent and independent pathways , 1993, Nature.

[66]  Bert Vogelstein,et al.  Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 , 1993, Nature.

[67]  C. Ingles,et al.  Direct interaction between the transcriptional activation domain of human p53 and the TATA box-binding protein. , 1993, The Journal of biological chemistry.

[68]  M. Oren,et al.  mdm2 expression is induced by wild type p53 activity. , 1993, The EMBO journal.

[69]  C. Finlay,et al.  The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth , 1993, Molecular and cellular biology.

[70]  G. Zambetti,et al.  Wild-type p53 binds to the TATA-binding protein and represses transcription. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[71]  B. Vogelstein,et al.  A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia , 1992, Cell.

[72]  A. Levine,et al.  Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[73]  P. Meltzer,et al.  Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.

[74]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[75]  M. Oren,et al.  Enhanced binding of a 95 kDa protein to p53 in cells undergoing p53‐mediated growth arrest. , 1992, The EMBO journal.

[76]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[77]  B. Vogelstein,et al.  Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.

[78]  A. Levine,et al.  p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts. , 1991, Genes & development.

[79]  M. Scheffner,et al.  A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. , 1991, The EMBO journal.

[80]  A. Kimchi,et al.  Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6 , 1991, Nature.

[81]  D. George,et al.  Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. , 1991, The EMBO journal.

[82]  A. Levine,et al.  Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. , 1991, Genes & development.

[83]  Arnold J. Levine,et al.  The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 , 1990, Cell.

[84]  B. Vogelstein,et al.  Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes. , 1990, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[85]  O. Halevy,et al.  Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53 , 1990, Cell.

[86]  E. Appella,et al.  Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[87]  A. Levine,et al.  The p53 protein and its interactions with the oncogene products of the small DNA tumor viruses. , 1990, Virology.

[88]  M. Oren,et al.  Wild-type p53 can inhibit oncogene-mediated focus formation. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[89]  A. Levine,et al.  The p53 proto-oncogene can act as a suppressor of transformation , 1989, Cell.

[90]  A. Levine,et al.  Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life , 1988, Molecular and cellular biology.

[91]  U. Francke,et al.  Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line , 1987, Somatic cell and molecular genetics.

[92]  W. Maltzman,et al.  UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells , 1984, Molecular and cellular biology.

[93]  Thierry Soussi,et al.  Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation , 1996, Nucleic Acids Res..

[94]  Thierry Soussi,et al.  P53 Gene Mutation: Software and Database , 1996, Nucleic Acids Res..

[95]  B. Quesnel,et al.  MDM2 gene amplification in human breast cancer. , 1994, European journal of cancer.

[96]  C. Harris,et al.  Correlation of p53 mutations with epidermal growth factor receptor overexpression and absence of mdm2 amplification in human esophageal carcinomas , 1993, Molecular carcinogenesis.

[97]  M. Ladanyi,et al.  MDM2 gene amplification in metastatic osteosarcoma. , 1993, Cancer research.